Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Press release, Helsinki, 29 December 2025 at 9 AM (EET)
Nexstim Receives NBS 6 System Order from New US Customer
Nexstim Plc ("Nexstim" or "Company") has received an order for an NBS 6 system from a new hospital customer in Northeastern United States.
NBS System 6 is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. The system helps neurosurgeons and radiotherapists plan their most delicate procedures, including tumor, epilepsy and AVM surgeries near eloquent tissue. Functional nTMS mapping provides accurate information on the anatomic relationship of the surgical targets with essential functions in the brain. In addition to its pre-surgical mapping capabilities, this NBS 6 system includes a therapy module that is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States.
Mikko Karvinen, CEO of Nexstim, comments: “This year we have celebrated 25 years since Nexstim was founded. After all these years of work on making our state-of-the-art nTMS technology available to help as many patients as possible, we still find every single new and existing customer extremely valuable to us.
This hospital is a renowned healthcare institution, and we expect them to gain great value from our product that extends to serve the needs of multiple departments.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE-marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com